Manufacturer record

Biocore Pharmaceuticals: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

4 batches manufactured by Biocore Pharmaceuticals (Himachal Pradesh) were declared Not of Standard Quality between December 2023 and February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

4 records linked to Biocore Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
4Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Dec 2023 to Feb 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

4
NSQ batches since 2023
4
Products affected
Labelling
Most common failure
Feb 2026
Latest alert

Flagged batches per year

2023 · 12025 · 12026 · 2

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Dextromethorphan Hbr, Chlorpheniramine Maleate & Phenylephrine HCl Syrup BL25-380AMfg 2025-11 · Exp 2027-10 The sample does not conform to claim as per Patent and Proprietary in respect to the Assay of Phenylephrine HydrochlorideAssay RDTL, ChandigarhCDSCO lab Feb 2026
Levosalbutamol, Ambroxol Hydrochloride & guaiphenesin Oral Drops BL24-249Mfg 2024-11 · Exp 2026-10 ContentOther Drugs Testing Laboratory, Chennai-06State lab Jan 2026
Rabeprazole sodium (GR) and domperidone (PR) Capsules BC24-144Mfg 2025-03 · Exp 2027-02 The contents of Rabeprazole Sodium found to be 16.36mg/cap (81.8%) against the label claim of 20 mg/cap in the above referred sample.Labelling State Drugs Laboratory, PunjabState lab Aug 2025
Telmisartan Tablets IP 40 mg (Telmibeck-40 Tablets) BT23-297Mfg 2023-07 · Exp 2025-06 Dissolution of TelmisartanDissolution RDTL ChandigarhCDSCO lab Dec 2023

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.